{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:45:39Z","timestamp":1770140739906,"version":"3.49.0"},"reference-count":40,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>JS005 is a novel anti-IL-17A monoclonal antibody. A Phase Ia study (Study 1) in healthy adults, followed by a Phase Ib\/II study (Study 2) in patients with moderate to severe plaque psoriasis (PsO), were designed to evaluate the safety, efficacy, and pharmacokinetic characteristics of JS005. Study 1 was a double-blind, randomized, placebo-controlled, single dose-escalation (15, 60, 150, 300, and 600 mg) study. Forty healthy participants were enrolled. Study 2 consisted of a dose-escalation (60, 150, 300, or 600 mg) phase Ib, and a multicentre, double-blind, placebo-controlled phase II administering JS005 150, 300 mg, or placebo once weekly from week 0 to 4 and once every 4 weeks from week 5 to 12. Forty and 143 patients were enrolled in phases Ib and II, respectively. The exposure of JS005 increased linearly with dosage, while the treatment-emergent adverse events did not show this trend. JS005 was well tolerated in both populations. In phase II of Study 2, the proportion of patients with at least a 75% improvement in the Psoriasis Area and Severity Index at week 12 was significantly higher in each JS005 group than in the placebo group (p\u2009&lt;\u20090.001 for all comparisons). JS005 was highly effective in PsO patients.<\/jats:p>","DOI":"10.2340\/actadv.v105.41105","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T08:16:18Z","timestamp":1742976978000},"page":"adv41105","source":"Crossref","is-referenced-by-count":1,"title":["Safety, Pharmacokinetics, and Efficiency of JS005, a Novel Anti-interleukin-17A Monoclonal Antibody, in Healthy Chinese Adults and Patients with Moderate to Severe Psoriasis"],"prefix":"10.2340","volume":"105","author":[{"given":"Lin","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huichen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanglei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Litao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangnian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"104700","unstructured":"Badri T, Kumar P, Oakley AM. Plaque psoriasis. In: StatPearls. Treasure Island, FL: StatPearls Publishing; August 8, 2023."},{"key":"104701","doi-asserted-by":"crossref","unstructured":"Kaul M, Jarvis P, Rozenberg I, Kolbinger F, Di Padova F, Calonder C, et al. First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol 2021; 35: 1143\u20131151.","DOI":"10.1111\/jdv.17071"},{"key":"104702","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17071","DOI":"10.1111\/jdv.17071"},{"key":"104703","doi-asserted-by":"crossref","unstructured":"Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches. Biomedicines 2021; 9: 1511.","DOI":"10.3390\/biomedicines9111511"},{"key":"104704","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/biomedicines9111511","DOI":"10.3390\/biomedicines9111511"},{"key":"104705","doi-asserted-by":"crossref","unstructured":"Griffiths CEM, van der Walt JM, Ashcroft DM, Flohr C, Naldi L, Nijsten T, et al. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol 2017; 177: e4\u20137.","DOI":"10.1111\/bjd.15610"},{"key":"104706","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.15610","DOI":"10.1111\/bjd.15610"},{"key":"104707","doi-asserted-by":"crossref","unstructured":"Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol 2018; 45: 264\u2013272.","DOI":"10.1111\/1346-8138.14139"},{"key":"104708","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1346-8138.14139","DOI":"10.1111\/1346-8138.14139"},{"key":"104709","doi-asserted-by":"crossref","unstructured":"Malakouti M, Brown G, Wang E, Koo J, Levin E. The role of IL-17 in psoriasis. J Dermatolog Treat 2015; 26: 41\u201344.","DOI":"10.3109\/09546634.2013.879093"},{"key":"104710","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/09546634.2013.879093","DOI":"10.3109\/09546634.2013.879093"},{"key":"104711","doi-asserted-by":"crossref","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med 2014; 371: 326\u2013338.","DOI":"10.1056\/NEJMoa1314258"},{"key":"104712","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1314258","DOI":"10.1056\/NEJMoa1314258"},{"key":"104713","doi-asserted-by":"crossref","unstructured":"Saeki H, Nakagawa H, Ishii T, Morisaki Y, Aoki T, Berclaz PY, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2015; 29: 1148\u20131155.","DOI":"10.1111\/jdv.12773"},{"key":"104714","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.12773","DOI":"10.1111\/jdv.12773"},{"key":"104715","doi-asserted-by":"crossref","unstructured":"Li X, Zheng J, Pan W, Zheng M, Lu Y, Li F, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study. Int J Dermatol Venerol 2022; 5: 181\u2013190.","DOI":"10.1097\/JD9.0000000000000244"},{"key":"104716","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/JD9.0000000000000244","DOI":"10.1097\/JD9.0000000000000244"},{"key":"104717","doi-asserted-by":"crossref","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375: 345\u2013356.","DOI":"10.1056\/NEJMoa1512711"},{"key":"104718","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1512711","DOI":"10.1056\/NEJMoa1512711"},{"key":"104719","doi-asserted-by":"crossref","unstructured":"Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386: 541\u2013551.","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"104720","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(15)60125-8","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"104721","doi-asserted-by":"crossref","unstructured":"Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet 2020; 395: 427\u2013440.","DOI":"10.1016\/S0140-6736(19)33161-7"},{"key":"104722","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(19)33161-7","DOI":"10.1016\/S0140-6736(19)33161-7"},{"key":"104723","doi-asserted-by":"crossref","unstructured":"Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2B trial. J Am Acad Dermatol 2018; 79: 277\u2013286.e10.","DOI":"10.1016\/j.jaad.2018.03.037"},{"key":"104724","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.03.037","DOI":"10.1016\/j.jaad.2018.03.037"},{"key":"104725","doi-asserted-by":"crossref","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373: 1318\u20131328.","DOI":"10.1056\/NEJMoa1503824"},{"key":"104726","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1503824","DOI":"10.1056\/NEJMoa1503824"},{"key":"104727","unstructured":"Bausch Health. Highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761032s014lbl.pdf"},{"key":"104728","doi-asserted-by":"crossref","unstructured":"Zhang M, Zhu X, Wu J, Huang Z, Zhao Z, Zhang X, et al. Hyperuricemia among Chinese adults: findings from two nationally representative cross-sectional surveys in 2015\u201316 and 2018\u201319. Front Immunol 2022; 12: 791983.","DOI":"10.3389\/fimmu.2021.791983"},{"key":"104729","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2021.791983","DOI":"10.3389\/fimmu.2021.791983"},{"key":"104730","doi-asserted-by":"crossref","unstructured":"Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis. Chin Med J (Engl) 2020; 133: 2665\u20132673.","DOI":"10.1097\/CM9.0000000000001163"},{"key":"104731","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/CM9.0000000000001163","DOI":"10.1097\/CM9.0000000000001163"},{"key":"104732","doi-asserted-by":"crossref","unstructured":"Mendes Roncada EV, Brambilla VR, Freitas Filitto B, Genta MP, Morgado de Abreu MAM. Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis. Case Rep Dermatol 2021; 13: 336\u2013339.","DOI":"10.1159\/000513467"},{"key":"104733","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000513467","DOI":"10.1159\/000513467"},{"key":"104734","doi-asserted-by":"crossref","unstructured":"Al-Janabi A, Foulkes AC, Griffiths CEM, Warren RB. Paradoxical eczema in patients with psoriasis receiving biologics: a case series. Clin Exp Dermatol 2022; 47: 1174\u20131178.","DOI":"10.1111\/ced.15130"},{"key":"104735","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ced.15130","DOI":"10.1111\/ced.15130"},{"key":"104736","doi-asserted-by":"crossref","unstructured":"Mengesha BG, Conti HR. The role of IL-17 in protection against mucosal candida infections. J Fungi (Basel) 2017; 3: 52.","DOI":"10.3390\/jof3040052"},{"key":"104737","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jof3040052","DOI":"10.3390\/jof3040052"},{"key":"104738","doi-asserted-by":"crossref","unstructured":"Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol 2017; 177: 47\u201362.","DOI":"10.1111\/bjd.15015"},{"key":"104739","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.15015","DOI":"10.1111\/bjd.15015"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/41105\/49631","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/41105\/49631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T08:17:38Z","timestamp":1742977058000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/41105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":40,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.41105","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}